Treatment
Rifampicin clinical trials
We’re tracking 31 recruiting studies that include Rifampicin, each written for real people, not researchers, below.
Recruiting studies
- NCT05383742RecruitingPhase 2
Compare 6- vs 9-month treatment for tuberculous meningitis
This Phase 2 study tests whether a shorter, stronger 6-month set of medicines works as well as the usual 9-month regimen for tuberculous meningitis (TB infection in the covering of the brain/spinal cord). The goal is to improve outcomes while reducing treatment time and exposure.
Porto AlegreAges 15 years+ - NCT06057519RecruitingPhase 3
Optimized rifampicin dosing for TB
This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.
TurinAges 18 years+ - NCT05902221RecruitingPhase 3
Rifampicin add-on for knee, hip, or shoulder implant infections
This Phase 3 trial tests whether adding rifampicin improves outcomes for implant infections caused by a specific germ (Cutibacterium acnes) after surgery. If you have such an infection and the germ is susceptible, you may be able to receive a rifampicin-based treatment plan.
AnnecyAges 18 years+ - NCT05268120Recruiting
Treatment to clear MRSA in people with difficult carriage
This study tests ways to get rid of MRSA bacteria in the body when it is “complicated,” such as having MRSA outside the nose or an ongoing MRSA infection. It may help reduce future MRSA problems or infections by lowering how long the bacteria stay in your body.
LeidenAges 18 years+ - NCT04672525RecruitingPhase 3
Rifabutin versus rifampicin for knee or hip staph implant infection
This Phase 3 trial compares two antibiotics—rifabutin and rifampicin—for treating staphylococcal (staph) infections around hip or knee joint implants when the implant is kept in place after cleaning (DAIR). It aims to see which drug works better to stop the infection from coming back.
AmiensAges 18 years+ - NCT05069688RecruitingPhase 1
Testing dolutegravir dosing in HIV and TB children
This study looks at the right way to dose dolutegravir (an HIV medicine) in young children who also have active tuberculosis (TB). Doctors will measure how the medicine moves through the body, especially when standard vs higher-dose rifampicin is used.
Ibadan, Oyo StateAges 4 weeks–5 years - NCT04521803RecruitingPhase 2
Higher-dose rifampicin for TB fluid around the heart
This Phase 2 study compares a higher dose versus the standard dose of rifampicin, a TB antibiotic, for people with TB-related fluid buildup around the heart. It aims to see which dose works better and is safe in improving TB pericarditis with fluid.
Mthatha, Eastern CapeAges 18 years+ - NCT05081401RecruitingPhase 3
All-oral shorter treatment for rifampicin-resistant TB
This Phase 3 trial tests a shorter, all-pill (oral) treatment plan for people with rifampicin-resistant pulmonary tuberculosis. It aims to improve treatment while reducing the burden of therapy, using a plan tailored to the individual.
Guiyang, GuizhouAges 16–75 - NCT05398679RecruitingPhase 4
Oral antibiotics versus IV antibiotics after heart infection
This trial compares taking antibiotics by mouth versus receiving antibiotics through a vein (outpatient IV) for an infection of the heart valve. It’s designed to see whether the oral option can work as well and safely, especially after initial treatment and surgery if needed.
Alicante, AlicanteAges 18 years+ - NCT05597280RecruitingPhase 3
Medicine given after exposure to prevent leprosy
This Phase 3 study tests whether taking preventive antibiotics after possible contact can stop leprosy from developing. If it works, it could protect people in affected communities from getting leprosy (and possibly related infections).
MoroniAges 2 years+ - NCT06172010RecruitingPhase 4
Rifampicin plus antibiotics for staph joint replacement infection
This study tests whether adding the antibiotic rifampicin to standard treatment works better than standard treatment alone for staph infections in hip or knee replacements. The goal is to find a more effective way to clear the infection and avoid more surgeries.
Leiden, Zuid HollansAges 18 years+ - NCT06748937RecruitingPhase 2
Testing alpibectir plus ethionamide for new TB
This study tests an experimental oral TB drug called alpibectir given together with ethionamide for people with newly diagnosed lung TB. The goal is to see how well the combination works and if it is safe.
Cape Town, Western CapeAges 18–65 - NCT05381194RecruitingPhase 4
Tested medicines for drug-resistant lung tuberculosis
This trial studies a specific drug combination (BPaLM) for adults with drug-resistant pulmonary (lung) tuberculosis. If you qualify, the goal is to see whether this treatment is effective and safe for your type of infection.
Seoul, Songpa-guAges 19 years+ - NCT03236987RecruitingPhase 3
Clarithromycin versus azithromycin for lung MAC infection
This Phase 3 trial compares two antibiotics—clarithromycin and azithromycin—to treat lung infection caused by Mycobacterium avium complex (MAC). It may help by showing which antibiotic works better and is safer for people who need MAC treatment.
Amiens, PicardieAges 18 years+ - NCT07084402RecruitingPhase 4
Effect of Contezolid on MAC lung disease
This trial tests whether the drug Contezolid can quickly kill the bacteria that cause MAC lung disease, a type of lung infection. It is for people who have not been treated for this infection in the last 3 months.
Beijing, Beijing MunicipalityAges 18–75 - NCT07313215Recruiting
Study of rifampin combo therapy for staph joint infections
This study tests whether adding rifampin to standard antibiotics works better for people with a staph infection in a joint replacement. It aims to find a more effective treatment for this type of infection.
Fuzhou, FujianAges 18–80 - NCT07213765RecruitingPhase 4
Short-term antibiotics for MAC lung disease
This trial tests whether a shorter course of antibiotics works for people with a specific type of lung infection caused by Mycobacterium avium complex (MAC). It aims to find a treatment that is just as effective but easier to complete.
Hefei, AnhuiAges 18–75 - NCT05807399RecruitingPhase 2
Step2c trial for new, drug-susceptible lung TB
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
LambarénéAges 18–65 - NCT05824871RecruitingPhase 3
Oral drug for rifampicin-resistant lung tuberculosis
This Phase 3 trial tests an oral medicine (Sudapyridine/WX-081) to treat people with rifampicin-resistant pulmonary tuberculosis. It compares how well the study drug works when you stop prior tuberculosis medicines and go through a short “washout” period first.
Beijing, Beijing MunicipalityAges 18–65 - NCT06114628RecruitingPhase 2
Finding the best treatment for lung TB (PARADIGM4TB)
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
ChisinauAges 18 years+ - NCT06192160RecruitingPhase 2
New TB drug combinations for drug-sensitive lung TB
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
GaboroneAges 18 years+ - NCT06199921RecruitingPhase 2
Atorvastatin plus TB treatment for new tuberculosis
This study tests whether adding the cholesterol drug atorvastatin to standard TB treatment helps people recover faster. It is for people with newly diagnosed, drug-sensitive tuberculosis who have not yet started treatment.
Zaria, Kaduna StateAges 12–65 - NCT06441006RecruitingPhase 2/Phase 3
Personalized treatment for rifampicin-resistant TB
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
UlaanbaatarAges 14 years+ - NCT06476210RecruitingPhase 4
New drug combo for drug-resistant tuberculosis
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
Hefei, AnhuiAges 18 years+
What Rifampicin is being studied for
Conditions with recruiting Rifampicin studies.
Common questions
- Are there clinical trials studying Rifampicin?
- Yes. Clin2 currently lists 31 recruiting studies that include Rifampicin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Rifampicin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Rifampicin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Rifampicin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.